Your browser doesn't support javascript.
loading
ATP synthase inhibitory factor 1 (IF1), a novel myokine, regulates glucose metabolism by AMPK and Akt dual pathways.
Lee, Hye Jeong; Moon, Jiyoung; Chung, InHyeok; Chung, Ji Hyung; Park, Chan; Lee, Jung Ok; Han, Jeong Ah; Kang, Min Ju; Yoo, Eun Hye; Kwak, So-Young; Jo, Garam; Park, Wonil; Park, Jonghoon; Kim, Kyoung Min; Lim, Soo; Ngoei, Kevin R W; Ling, Naomi X Y; Oakhill, Jonathan S; Galic, Sandra; Murray-Segal, Lisa; Kemp, Bruce E; Mantzoros, Christos S; Krauss, Ronald M; Shin, Min-Jeong; Kim, Hyeon Soo.
Afiliación
  • Lee HJ; Department of Anatomy, Korea University College of Medicine, Seoul, South Korea.
  • Moon J; Department of Public Health Sciences, Korea University, Seoul, South Korea.
  • Chung I; Laboratory of Gene Regulation and Metabolism, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
  • Chung JH; Department of Public Health Sciences, Korea University, Seoul, South Korea.
  • Park C; Department of Biotechnology, CHA University, Pocheon, South Korea.
  • Lee JO; Department of Biotechnology, CHA University, Pocheon, South Korea.
  • Han JA; Department of Anatomy, Korea University College of Medicine, Seoul, South Korea.
  • Kang MJ; Department of Anatomy, Korea University College of Medicine, Seoul, South Korea.
  • Yoo EH; Department of Anatomy, Korea University College of Medicine, Seoul, South Korea.
  • Kwak SY; Department of Public Health Sciences, Korea University, Seoul, South Korea.
  • Jo G; Department of Public Health Sciences, Korea University, Seoul, South Korea.
  • Park W; Department of Public Health Sciences, Korea University, Seoul, South Korea.
  • Park J; Department of Physical Education, Korea University, Seoul, South Korea.
  • Kim KM; Department of Physical Education, Korea University, Seoul, South Korea.
  • Lim S; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Ngoei KRW; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Ling NXY; Protein Chemistry and Metabolism, University of Melbourne, Fitzroy, Victoria, Australia.
  • Oakhill JS; Metabolic Signaling Laboratory, St Vincenf's Institute of Medical Research, University of Melbourne, Fitzroy, Victoria, Australia.
  • Galic S; Metabolic Signaling Laboratory, St Vincenf's Institute of Medical Research, University of Melbourne, Fitzroy, Victoria, Australia.
  • Murray-Segal L; Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia.
  • Kemp BE; Protein Chemistry and Metabolism, University of Melbourne, Fitzroy, Victoria, Australia.
  • Mantzoros CS; Protein Chemistry and Metabolism, University of Melbourne, Fitzroy, Victoria, Australia.
  • Krauss RM; Protein Chemistry and Metabolism, University of Melbourne, Fitzroy, Victoria, Australia.
  • Shin MJ; Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia.
  • Kim HS; Division of Endocrinology, Beth-Israel Deaconess Medical Center-Harvard Medical School, Boston, Massachusetts, USA.
FASEB J ; 33(12): 14825-14840, 2019 12.
Article en En | MEDLINE | ID: mdl-31670977
ABSTRACT
ATPase inhibitory factor 1 (IF1) is an ATP synthase-interacting protein that suppresses the hydrolysis activity of ATP synthase. In this study, we observed that the expression of IF1 was up-regulated in response to electrical pulse stimulation of skeletal muscle cells and in exercized mice and healthy men. IF1 stimulates glucose uptake via AMPK in skeletal muscle cells and primary cultured myoblasts. Reactive oxygen species and Rac family small GTPase 1 (Rac1) function in the upstream and downstream of AMPK, respectively, in IF1-mediated glucose uptake. In diabetic animal models, the administration of recombinant IF1 improved glucose tolerance and down-regulated blood glucose level. In addition, IF1 inhibits ATP hydrolysis by ß-F1-ATPase in plasma membrane, thereby increasing extracellular ATP and activating the protein kinase B (Akt) pathway, ultimately leading to glucose uptake. Thus, we suggest that IF1 is a novel myokine and propose a mechanism by which AMPK and Akt contribute independently to IF1-mediated improvement of glucose tolerance impairment. These results demonstrate the importance of IF1 as a potential antidiabetic agent.-Lee, H. J., Moon, J., Chung, I., Chung, J. H., Park, C., Lee, J. O., Han, J. A., Kang, M. J., Yoo, E. H., Kwak, S.-Y., Jo, G., Park, W., Park, J., Kim, K. M., Lim, S., Ngoei, K. R. W., Ling, N. X. Y., Oakhill, J. S., Galic, S., Murray-Segal, L., Kemp, B. E., Mantzoros, C. S., Krauss, R. M., Shin, M.-J., Kim, H. S. ATP synthase inhibitory factor 1 (IF1), a novel myokine, regulates glucose metabolism by AMPK and Akt dual pathways.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas / Mioblastos / Glucosa Tipo de estudio: Prognostic_studies Límite: Adult / Animals / Humans / Male Idioma: En Revista: FASEB J Asunto de la revista: BIOLOGIA / FISIOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Corea del Sur

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas / Mioblastos / Glucosa Tipo de estudio: Prognostic_studies Límite: Adult / Animals / Humans / Male Idioma: En Revista: FASEB J Asunto de la revista: BIOLOGIA / FISIOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Corea del Sur